Posted by Friends of FSH Research on Jan 30, 2020
During our recent patient information meeting, a Fulcrum representative was asked if they were going to apply for an Orphan Drug Designation. The question was essentially deferred, but apparently it was in process at that time, and has now been approved.
What this essentially means is that Fulcrum has more of an incentive to invest in the proposed therapeutic and clinical trials for it. They can receive tax credits, and an exclusive market for seven years.
See BioSpace article.
Connect with us on social media